
Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps
Bioregnum
The view from Endpoints
First came the onslaught of media reports. Then came the outraged letter from the US Senators followed by the launch of a House probe and a bipartisan demand for documents. Now, a few weeks in, comes the first piece of legislation aimed at killing the source of the outrage.
Allergan’s Mohawk gambit on the patent front is fast becoming a textbook study in how to shoot yourself in the foot while attracting a large and unsympathetic crowd.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.